Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives

References

• Nicholson KG. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, Editors. Textbook of influenza. Oxford: Blackwell Science; 1998;219-64
   Google Scholar
• Song JY, Cheong HJ, Choi SH, et al. Hospital-based influenza surveillance in Korea: hospital-based influenza morbidity and mortality study group. J Med Virol 2013;85:910-17
   PubMed Web of Science ®Google Scholar
• Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 2013;98:174-85
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86
   PubMed Web of Science ®Google Scholar
• National Evidence-based Healthcare Collaborating Agency. Disease burden of seasonal influenza and vaccine effectiveness in Korea. 2010. Available from: www.neca.re.kr/center/researcher/report_view.jsp?boardNo=GA&seq=7&q=626f6172644e6f3d4741 [Last accessed 2015]
   Google Scholar
• Suh M, Kang DR, Lee DH, et al. Socioeconomic burden of influenza in the Republic of Korea, 2007-2010. PLoS One 2013;8:e84121
   PubMed Web of Science ®Google Scholar
• Lee JS, Shin KC, Na BK, et al. Influenza surveillance in Korea: establishment and first results of an epidemiological and virological surveillance scheme. Epidemiol Infect 2007;135:1117-23
   PubMed Web of Science ®Google Scholar
• Seo YB, Song JY, Cheong HJ, et al. Hospital-based influenza morbidity and mortality surveillance system for influenza-like illnesses: a comparison with national influenza surveillance systems. Influenza Other Respir Viruses 2014;8:17-20
   Web of Science ®Google Scholar
• Korea Center for Disease Control and Prevention (KCDC). Influenza A(H1N1) virus resistance to oseltamivir - Fourth quarter 2008 to 31 January 2009. Public Health Weekly Report 2009;2:220-1
   Google Scholar
• Korea Center for Disease Control and Prevention (KCDC). Korean Influenza Sentinel Surveillance Report, 2013-2014. Public Health Weekly Report 2014;7:1089-98
   Google Scholar
• Lee DH, Shin SS, Jun BY, Lee JK. [National level response to pandemic (H1N1) 2009]. J Prev Med Public Health 2010;43:99-104
   PubMedGoogle Scholar
• Choi WS, Kim WJ, Cheong HJ. [The evaluation of policies on 2009 influenza pandemic in Korea]. J Prev Med Public Health 2010;43:105-8
   PubMedGoogle Scholar
• Choi K, Cho SI, Hashizume M, Kim H. Epidemiological characteristics of novel influenza A (H1N1) in antiviral drug users in Korea. PLoS One 2012;7:e47634
   PubMed Web of Science ®Google Scholar
• Kim JH, Yoo HS, Lee JS, et al. The spread of pandemic H1N1 2009 by age and region and the comparison among monitoring tools. J Korean Med Sci 2010;25:1109-12
   PubMed Web of Science ®Google Scholar
• Garske T, Legrand J, Donnelly CA, et al. Assessing the severity of the novel influenza A/H1N1 pandemic. BMJ 2009;339:b2840
   PubMed Web of Science ®Google Scholar
• Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014;2:395-404
   PubMed Web of Science ®Google Scholar
• Hong SB, Choi EY, Kim SH, et al. Epidemiological analysis of critically ill adult patients with pandemic influenza A(H1N1) in South Korea. Epidemiol Infect 2013;141:1070-9
   PubMed Web of Science ®Google Scholar
• Kang SJ, Park KH, Kee SJ, et al. Virological clearance rate of high-dose oseltamivir or triple-combination antiviral therapy in complicated 2009 pandemic influenza A (H1N1) infection. Jpn J Infect Dis 2013;66:425-7
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim JH, Shin SY, et al. Fatal cases of 2009 pandemic influenza A (H1N1) in Korea. J Korean Med Sci 2011;26:22-7
   PubMed Web of Science ®Google Scholar
• Song JY, Cheong HJ, Heo JY, et al. Clinical, laboratory and radiologic characteristics of 2009 pandemic influenza A/H1N1 pneumonia: primary influenza pneumonia versus concomitant/secondary bacterial pneumonia. Influenza Other Respir Viruses 2011;5:e535-43
   PubMed Web of Science ®Google Scholar
• Ko JH, Kim JH, Kang JH, et al. Characteristics of hospitalized children with 2009 pandemic influenza A (H1N1): a multicenter study in Korea. J Korean Med Sci 2012;27:408-15
   PubMed Web of Science ®Google Scholar
• Lee E, Seo JH, Kim HY, et al. Clinical characteristics and outcomes among pediatric patients hospitalized with pandemic influenza A/H1N1 2009 infection. Korean J Pediatr 2011;54:329-34
   PubMedGoogle Scholar
• Rhim JW, Lee KY, Youn YS, et al. Epidemiological and clinical characteristics of childhood pandemic 2009 H1N1 virus infection: an observational cohort study. BMC Infect Dis 2011;11:225
   PubMed Web of Science ®Google Scholar
• Lee N, Hui DS, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. Clin Infect Dis 2013;57:1511-19
   PubMed Web of Science ®Google Scholar
• Kim WY, Young Suh G, Huh JW, et al. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother 2011;55:5703-9
   PubMed Web of Science ®Google Scholar
• Smee DF, Hurst BL, Wong MH, et al. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother 2009;53:2120-8
   PubMed Web of Science ®Google Scholar
• Hata A, Akashi-Ueda R, Takamatsu K, Matsumura T. Safety and efficacy of peramivir for influenza treatment. Drug Des Devel Ther 2014;8:2017-38
   PubMed Web of Science ®Google Scholar
• Choi WS, Lee J, Lee H-Y, et al. Clinical practice guideline for antiviral treatment and chemoprophylaxis of seasonal influenza. Infect Chemother 2012;44:233-49
   Google Scholar
• Choi WS, Noh JY, Song JY, et al. Comparison of clinical effectiveness of oseltamivir and peramivir against seasonal influenza in Korean adults. In: 2014 Congress of the Korean Society for Chemotherapy &The Korean Society of Infectious Diseases. The Korean Society of Infectious Diseases, Seoul: 2014
   Google Scholar
• Choi WS, Baek JH, Seo YB, et al. Severe influenza treatment guideline. Korean J Intern Med 2014;29:132-47
   PubMed Web of Science ®Google Scholar
• Yang SG, Cao B, Liang LR, et al. Antiviral therapy and outcomes of patients with pneumonia caused by influenza a pandemic (H1N1) virus. PLoS One 2012;7:e29652
   PubMed Web of Science ®Google Scholar
• South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ 2013;346:f3039
   PubMed Web of Science ®Google Scholar
• Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60:1-24
   PubMedGoogle Scholar
• Escuret V, Cornu C, Boutitie F, et al. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections. Antiviral Res 2012;96:130-7
   PubMed Web of Science ®Google Scholar
• Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010;7:e1000362
   PubMed Web of Science ®Google Scholar
• Fraaij PL, van der Vries E, Beersma MF, et al. Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. J Infect Dis 2011;204:777-82
   PubMed Web of Science ®Google Scholar
• Petersen E, Keld DB, Ellermann-Eriksen S, et al. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Scand J Infect Dis 2011;43:495-503
   PubMed Web of Science ®Google Scholar
• Kubo S, Tomozawa T, Kakuta M, et al. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother 2010;54:1256-64
   PubMed Web of Science ®Google Scholar
• Ishizuka H, Yoshiba S, Okabe H, Yoshihara K. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J Clin Pharmacol 2010;50:1319-29
   PubMed Web of Science ®Google Scholar
• Samson M, Abed Y, Desrochers FM, et al. Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir. Antimicrob Agents Chemother 2014;58:5220-8
   PubMed Web of Science ®Google Scholar
• Yamashita M, Tomozawa T, Kakuta M, et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009;53:186-92
   PubMed Web of Science ®Google Scholar
• Watanabe A, Chang SC, Kim MJ, et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 2010;51:1167-75
   PubMed Web of Science ®Google Scholar
• Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010;54:2575-82
   PubMed Web of Science ®Google Scholar
• Ikematsu H, Kawai N, Iwaki N, Kashiwagi S. Continued effectiveness of laninamivir octanate hydrate for influenza treatment in Japan: comparison between the 2011-2012 and 2012-2013 influenza seasons. J Infect Chemother 2014;20:799-803
   PubMed Web of Science ®Google Scholar
• Meijer A, Rebelo-de-Andrade H, Correia V, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antiviral Res 2014;110:31-41
   PubMed Web of Science ®Google Scholar
• Takashita E, Meijer A, Lackenby A, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antiviral Res 2015;117:27-38
   PubMed Web of Science ®Google Scholar
• Furuta Y, Takahashi K, Shiraki K, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009;82:95-102
   PubMed Web of Science ®Google Scholar
• Sidwell RW, Barnard DL, Day CW, et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007;51:845-51
   PubMed Web of Science ®Google Scholar
• Kiso M, Takahashi K, Sakai-Tagawa Y, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 2010;107:882-7
   PubMed Web of Science ®Google Scholar
• Park S, Kim JI, Lee I, et al. Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice. PLoS One 2014;9:e101325
   PubMed Web of Science ®Google Scholar
• Smee DF, Tarbet EB, Furuta Y, et al. Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice. Future Virol 2013;8:1085-94
   PubMed Web of Science ®Google Scholar
• Hayden FG. Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respir Viruses 2013;7(Suppl 1):63-75
   PubMed Web of Science ®Google Scholar
• Toyama Chemical Co. The new drug application approval of “AVIGAN® Tablet 200mg” in Japan for the anti-influenza virus drug. 2014. Available from: www.toyama-chemical.co.jp/eng/news/news140324e.html [Last accessed 25 Mar 2015]
   Google Scholar
• Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006;50:1470-9
   PubMed Web of Science ®Google Scholar
• Triana-Baltzer GB, Gubareva LV, Nicholls JM, et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One 2009;4:e7788
   PubMed Web of Science ®Google Scholar
• Marjuki H, Mishin VP, Chesnokov AP, et al. An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality. J Infect Dis 2014;210:435-40
   PubMed Web of Science ®Google Scholar
• Belser JA, Lu X, Szretter KJ, et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007;196:1493-9
   PubMed Web of Science ®Google Scholar
• Chan RW, Chan MC, Wong AC, et al. DAS181 inhibits H5N1 influenza virus infection of human lung tissues. Antimicrob Agents Chemother 2009;53:3935-41
   PubMed Web of Science ®Google Scholar
• Moss RB, Hansen C, Sanders RL, et al. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 2012;206:1844-51
   PubMed Web of Science ®Google Scholar
• Triana-Baltzer GB, Sanders RL, Hedlund M, et al. Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181. J Antimicrob Chemother 2011;66:15-28
   PubMed Web of Science ®Google Scholar
• Rossignol JF, La Frazia S, Chiappa L, et al. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009;284:29798-808
   PubMed Web of Science ®Google Scholar
• Rossignol JF. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res 2014;110:94-103
   PubMed Web of Science ®Google Scholar
• Haffizulla J, Hartman A, Hoppers M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 2014;14:609-18
   PubMed Web of Science ®Google Scholar
• Safety and efficacy study of nitazoxanide in the treatment of acute uncomplicated influenza. Available from: https://clinicaltrials.gov/ct2/show/NCT01610245
   Google Scholar
• Belardo G, Cenciarelli O, La Frazia S, et al. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza a viruses in vitro. Antimicrob Agents Chemother 2015;59:1061-9
   PubMed Web of Science ®Google Scholar
• Noh JY, Kim WJ. Influenza vaccines: unmet needs and recent developments. Infect Chemother 2013;45:375-86
   PubMedGoogle Scholar
• Clementi N, Criscuolo E, Castelli M, Clementi M. Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. New Microbiol 2012;35:399-406
   PubMed Web of Science ®Google Scholar
• Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011;333:850-6
   PubMed Web of Science ®Google Scholar
• Dreyfus C, Laursen NS, Kwaks T, et al. Highly conserved protective epitopes on influenza B viruses. Science 2012;337:1343-8
   PubMed Web of Science ®Google Scholar
• Celltrion. Celltrion announces positive data from phase 1 trial of a novel therapeutic antibody CT-P27. 2013. Available from: www.celltrion.com/en/COMPANY/notice_view.asp?idx=414&code=ennews&intNowPage=1&menu_num=&align_year=all [Last accessed 30 Mar 2015]
   Google Scholar
• Song A, Myojo K, Laudenslager J, et al. Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates. Antiviral Res 2014;111:60-8
   PubMed Web of Science ®Google Scholar
• Wang R, Song A, Levin J, et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 2008;80:168-77
   PubMed Web of Science ®Google Scholar
• Ozawa T, Jin A, Tajiri K, et al. Characterization of a fully human monoclonal antibody against extracellular domain of matrix protein 2 of influenza A virus. Antiviral Res 2011;91:283-7
   PubMed Web of Science ®Google Scholar
• Ramos EL, Mitcham JL, Koller TD, et al. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. J Infect Dis 2015;211:1038-44
   PubMed Web of Science ®Google Scholar
• Takashita E, Ejima M, Fujisaki S, et al. A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November 2013 to February 2014. In: The Fifth ESWI Influenza Conference, 16 September 2014, Riga, Latvia
   Google Scholar
• Pascua PN, Choi YK. Zoonotic infections with avian influenza A viruses and vaccine preparedness: a game of “mix and match”. Clin Exp Vaccine Res 2014;3:140-8
   PubMedGoogle Scholar
• Safety study of anti-influenza virus monoclonal antibody to treat Influenza. Available from: https://clinicaltrials.gov/ct2/show/NCT01390025
   Google Scholar
• Influenza virus challenge study to test monoclonal antibody TCN-032 as a treatment for influenza. Available from: https://clinicaltrials.gov/ct2/show/NCT01719874
   Google Scholar
• Assessment of CR6261, a monoclonal antibody against the influenza a virus. Available from: https://clinicaltrials.gov/ct2/show/NCT01406418
   Google Scholar
• Assessment of CR8020, a monoclonal antibody against influenza a viruses. Available from: https://clinicaltrials.gov/ct2/show/NCT01756950
   Google Scholar
• Assessment of efficacy of CR8020 and CR6261, monoclonal antibodies, against influenza infection. Available from: https://clinicaltrials.gov/ct2/show/NCT01992276
   Google Scholar
• Evaluation of the protective efficacy and safety of CR8020 in an influenza challenge. Available from: https://clinicaltrials.gov/ct2/show/NCT01938352
   Google Scholar
• Study in healthy volunteers to evaluate the efficacy and safety of CR6261 in an H1N1 influenza healthy human challenge model. Available from: https://clinicaltrials.gov/ct2/show/NCT02371668
   Google Scholar
• To Evaluate the efficacy and safety of CT-P27 in an influenza challenge model. Available from: https://clinicaltrials.gov/ct2/show/NCT02071914
   Google Scholar
• Safety and pharmacokinetics study of human monoclonal antibody (FGI-101-1A6). Available from: https://clinicaltrials.gov/ct2/show/NCT01299142
   Google Scholar
• A study of VIS410 to assess safety and pharmacokinetics. Available from: https://clinicaltrials.gov/ct2/show/NCT02045472
   Google Scholar
• Phase 1 placebo-controlled,dose-escalation study to evaluate the safety and pharmacokinetics of MEDI8852 in adults. Available from: https://clinicaltrials.gov/ct2/show/NCT02350751
   Google Scholar